Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Roundup: Innovent I/O Setback, Adagene, Hua Bag Millions, WuXi Relisting

Executive Summary

China biotechs blossom with millions in new funding for antibody developer Adagene and diabetes drug maker Hua Medicine, and a planned CNY5.7bn Shanghai listing for WuXi Apptec. However, national innovation darling Innovent Bio has withdrawn its PD-1 approval filing, dealing a setback to a crowded area.

You may also be interested in...



China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval

Medicines regulators have cleared Innovent Biologics's anti-PD-1 therapy, sintilimab, for classical Hodgkin's lymphoma in China, where late-stage studies as a first-line therapy for advanced esopheageal cancer have also just started.

Opdivo Approval Opens China I-O Doors But Pricing Key

China approves first immuno-oncology drug in the form of BMS’s Opdivo for lung cancer, opening up a new potentially huge market for the class, but much will depend on pricing and reimbursement policies.

Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio

Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC100669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel